Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.

Tytuł:
Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Autorzy:
Tarpley M; Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC 27707, USA.
Oladapo HO; Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC 27707, USA; INBS PhD Program, North Carolina Central University, Durham, NC 27707, USA.
Strepay D; Department of Biological and Biomedical Sciences, North Carolina Central University, Durham, NC 27707, USA.
Caligan TB; Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC 27707, USA.
Chdid L; Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC 27707, USA.
Shehata H; Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC 27707, USA; INBS PhD Program, North Carolina Central University, Durham, NC 27707, USA.
Roques JR; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27514, USA.
Thomas R; Department of Pharmaceutical Sciences; North Carolina Central University, Durham, NC 27707, USA.
Laudeman CP; Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC 27707, USA.
Onyenwoke RU; Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC 27707, USA; Department of Pharmaceutical Sciences; North Carolina Central University, Durham, NC 27707, USA.
Darr DB; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27514, USA.
Williams KP; Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC 27707, USA; Department of Pharmaceutical Sciences; North Carolina Central University, Durham, NC 27707, USA. Electronic address: .
Źródło:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2021 Jul 01; Vol. 162, pp. 105821. Date of Electronic Publication: 2021 Mar 27.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: Amsterdam : Elsevier Science B.V
Original Publication: Amsterdam ; New York : Elsevier, c1993-
MeSH Terms:
Monoamine Oxidase Inhibitors*/pharmacology
Neoplasms*
Antineoplastic Agents/*pharmacology
Protein Serine-Threonine Kinases/*antagonists & inhibitors
Protein-Tyrosine Kinases/*antagonists & inhibitors
Carbolines ; Harmine/pharmacology ; High-Throughput Screening Assays ; Humans ; Monoamine Oxidase ; Dyrk Kinases
References:
Toxicol In Vitro. 2014 Apr;28(3):403-10. (PMID: 24373881)
J Cell Sci. 1999 Dec;112 ( Pt 23):4405-14. (PMID: 10564658)
Mech Ageing Dev. 2017 Jan;161(Pt A):141-148. (PMID: 27282658)
J Cell Mol Med. 2010 Apr;14(4):1003-13. (PMID: 20082656)
FASEB J. 1995 May;9(8):576-96. (PMID: 7768349)
Cancer Res. 1973 Dec;33(12):3231-8. (PMID: 4357355)
J Biomol Screen. 1999;4(2):67-73. (PMID: 10838414)
Cell Chem Biol. 2016 Apr 21;23(4):435-41. (PMID: 27049669)
Biochem Pharmacol. 2008 Dec 1;76(11):1389-94. (PMID: 18599021)
Science. 2002 Dec 6;298(5600):1912-34. (PMID: 12471243)
J Neurochem. 2008 Mar;104(5):1333-44. (PMID: 18005339)
Genes Dev. 2011 Apr 15;25(8):801-13. (PMID: 21498570)
CNS Neurol Disord Drug Targets. 2014 Feb;13(1):26-33. (PMID: 24152332)
J Med Chem. 2017 Mar 9;60(5):2052-2070. (PMID: 28206758)
PLoS One. 2009 Oct 21;4(10):e7540. (PMID: 19844572)
Med Biol. 1981 Feb;59(1):21-34. (PMID: 7022042)
Molecules. 2020 Apr 23;25(8):. (PMID: 32340326)
Molecules. 2017 Oct 27;22(11):. (PMID: 29077046)
Planta Med. 2012 Jun;78(10):951-6. (PMID: 22673832)
Arch Biochem Biophys. 1997 Jan 1;337(1):137-42. (PMID: 8990278)
FASEB J. 2011 Feb;25(2):449-62. (PMID: 21048044)
Oncotarget. 2016 Feb 9;7(6):7134-48. (PMID: 26784250)
Oncotarget. 2017 Jan 3;8(1):833-845. (PMID: 27903983)
Future Med Chem. 2018 Jun 1;10(12):1435-1448. (PMID: 29788780)
Biochem Biophys Res Commun. 1997 Aug 18;237(2):465-9. (PMID: 9268735)
Bioorg Med Chem Lett. 2014 Oct 15;24(20):4854-60. (PMID: 25240617)
Sci Transl Med. 2016 Aug 31;8(354):354re3. (PMID: 27582061)
Bioorg Med Chem Lett. 2012 Jan 1;22(1):168-71. (PMID: 22154664)
Dis Model Mech. 2016 Aug 1;9(8):839-48. (PMID: 27483355)
J Neurochem. 2015 May;133(3):440-51. (PMID: 25556849)
Cells. 2020 Jun 16;9(6):. (PMID: 32560058)
Cancer Cell Int. 2018 Jun 07;18:82. (PMID: 29977157)
J Biol Chem. 2002 Sep 20;277(38):35156-61. (PMID: 12138125)
Bioorg Med Chem. 2011 Jan 1;19(1):134-44. (PMID: 21183355)
J Nucl Med. 2008 Jan;49(1):129-134. (PMID: 18077531)
Biochem J. 2007 Dec 15;408(3):297-315. (PMID: 17850214)
Data Brief. 2021 May 30;37:107189. (PMID: 34141844)
Tremor Other Hyperkinet Mov (N Y). 2012;2:. (PMID: 23440018)
FEBS J. 2011 Jan;278(2):236-45. (PMID: 21156028)
FEBS J. 2011 Jan;278(2):246-56. (PMID: 21126318)
J Biomol Struct Dyn. 2022 Jun;40(9):3965-3978. (PMID: 33252029)
Sci Rep. 2019 May 23;9(1):7782. (PMID: 31123330)
Sci Rep. 2016 Oct 31;6:36132. (PMID: 27796319)
FEBS Lett. 2012 Jul 4;586(14):2016-25. (PMID: 22609357)
CNS Neurosci Ther. 2013 Dec;19(12):926-36. (PMID: 24165291)
Hepatobiliary Pancreat Dis Int. 2011 Dec;10(6):599-604. (PMID: 22146623)
J Dev Biol. 2017 Nov 21;5(4):. (PMID: 29615569)
Expert Opin Drug Discov. 2008 Jun;3(6):607-621. (PMID: 19662101)
J Am Chem Soc. 2013 Feb 6;135(5):1669-72. (PMID: 23330637)
Oncotarget. 2015 Apr 20;6(11):8988-9001. (PMID: 25940702)
J Cancer Res Ther. 2019;15(4):889-898. (PMID: 31436248)
J Neurooncol. 2013 Mar;112(1):39-48. (PMID: 23392846)
Molecules. 2018 Nov 08;23(11):. (PMID: 30413113)
Mol Cell Oncol. 2015 Jan 30;2(1):e970048. (PMID: 27308401)
Biochem Biophys Res Commun. 2017 Jul 29;489(3):332-338. (PMID: 28551404)
PLoS One. 2015 Jul 20;10(7):e0132453. (PMID: 26192590)
Biochem J. 2001 Nov 1;359(Pt 3):497-505. (PMID: 11672423)
Molecules. 2014 Sep 26;19(10):15411-39. (PMID: 25264830)
Biochem J. 2001 May 1;355(Pt 3):609-15. (PMID: 11311121)
FEBS J. 2008 Dec;275(24):6268-80. (PMID: 19016842)
Mini Rev Med Chem. 2012 Nov;12(13):1315-29. (PMID: 23016545)
Arch Biochem Biophys. 2011 Mar 15;507(2):212-8. (PMID: 21185805)
Diabetologia. 2014 May;57(5):960-9. (PMID: 24477974)
PLoS One. 2012;7(12):e52162. (PMID: 23300602)
Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40. (PMID: 19969454)
MethodsX. 2021 May 13;8:101383. (PMID: 34430279)
J Neural Transm (Vienna). 2011 Jul;118(7):1031-41. (PMID: 21190052)
J Biomol Screen. 2009 Sep;14(8):924-35. (PMID: 19564447)
Bioorg Med Chem Lett. 2014 Nov 1;24(21):5037-40. (PMID: 25248682)
RNA Biol. 2013 Feb;10(2):321-33. (PMID: 23324600)
Cell Death Dis. 2019 Mar 25;10(4):282. (PMID: 30910997)
J Biomol Screen. 2008 Jul;13(6):527-37. (PMID: 18566484)
PeerJ. 2013 Oct 01;1:e174. (PMID: 24109558)
Eur J Med Chem. 2013 Feb;60:135-43. (PMID: 23291116)
Cancer Lett. 2017 Dec 28;411:136-149. (PMID: 28965853)
Bioorg Med Chem Lett. 1999 Dec 6;9(23):3319-24. (PMID: 10612592)
J Biomed Res. 2013 Jul;27(4):254-71. (PMID: 23885265)
Elife. 2020 Aug 06;9:. (PMID: 32758357)
Nat Commun. 2010 Oct 05;1:86. (PMID: 20981014)
Eur J Med Chem. 2012 Nov;57:225-33. (PMID: 23063566)
J Biol Chem. 2008 May 23;283(21):14345-54. (PMID: 18378682)
Drug Test Anal. 2014 Jul-Aug;6(7-8):607-13. (PMID: 24115740)
Phytomedicine. 2017 May 15;28:10-18. (PMID: 28478808)
Carcinogenesis. 2017 Mar 1;38(3):252-260. (PMID: 28426875)
Eur J Pharmacol. 1994 Jan 24;252(1):51-9. (PMID: 8149995)
J Med Chem. 2018 Sep 13;61(17):7687-7699. (PMID: 30059217)
ScientificWorldJournal. 2006 Jun 17;6:1911-22. (PMID: 17205196)
Depress Res Treat. 2012;2012:987397. (PMID: 21969912)
F1000Res. 2017 Jan 13;6:42. (PMID: 28163906)
Bioorg Med Chem. 2010 Sep 15;18(18):6613-24. (PMID: 20708941)
Molecules. 2020 Dec 16;25(24):. (PMID: 33339338)
Biochem Biophys Res Commun. 2017 Sep 23;491(3):767-772. (PMID: 28735864)
Cancers (Basel). 2020 Jul 29;12(8):. (PMID: 32751160)
Biochem Biophys Res Commun. 2005 Jan 14;326(2):378-86. (PMID: 15582589)
Diabetes. 2016 Jun;65(6):1660-71. (PMID: 26953159)
Anal Biochem. 2006 Dec 15;359(2):238-46. (PMID: 17084801)
Methods Mol Biol. 2009;565:107-26. (PMID: 19551359)
J Clin Invest. 2013 Jun;123(6):2475-87. (PMID: 23635774)
Phytother Res. 2010 Jan;24(1):146-9. (PMID: 19548284)
Nat Struct Mol Biol. 2010 Jun;17(6):718-25. (PMID: 20512148)
Bioorg Med Chem. 2004 Sep 1;12(17):4613-23. (PMID: 15358288)
Int J Cancer. 2005 May 1;114(5):675-82. (PMID: 15609303)
Nat Med. 2015 Apr;21(4):383-8. (PMID: 25751815)
PLoS One. 2011 May 06;6(5):e19264. (PMID: 21573099)
J Biomol Screen. 2012 Sep;17(8):1005-17. (PMID: 22706350)
ChemMedChem. 2017 Jun 21;12(12):932-939. (PMID: 28264138)
Pharmacol Ther. 2015 Jul;151:87-98. (PMID: 25795597)
Eur J Med Chem. 2005 Mar;40(3):249-57. (PMID: 15725494)
FEBS J. 2009 Nov;276(21):6324-37. (PMID: 19796173)
Arch Biochem Biophys. 2015 Feb 1;567:66-74. (PMID: 25529135)
Nat Biotechnol. 2011 Oct 30;29(11):1039-45. (PMID: 22037377)
Eur J Pharmacol. 1972 May;18(2):284-6. (PMID: 5037388)
Br J Pharmacol Chemother. 1959 Sep;14:350-4. (PMID: 13792135)
Grant Information:
SC2 CA137844 United States CA NCI NIH HHS; U54 CA156735 United States CA NCI NIH HHS; U54 MD012392 United States MD NIMHD NIH HHS; R15 CA208651 United States CA NCI NIH HHS; P20 CA202924 United States CA NCI NIH HHS
Contributed Indexing:
Keywords: DYRK1A; glioma; harmine; harmol; hedgehog; high throughput screening; monoamine oxidase A
Substance Nomenclature:
0 (Antineoplastic Agents)
0 (Carbolines)
0 (Monoamine Oxidase Inhibitors)
4FHH5G48T7 (Harmine)
EC 1.4.3.4 (Monoamine Oxidase)
EC 2.7.10.1 (Protein-Tyrosine Kinases)
EC 2.7.11.1 (Protein Serine-Threonine Kinases)
Entry Date(s):
Date Created: 20210330 Date Completed: 20210621 Latest Revision: 20231213
Update Code:
20240105
PubMed Central ID:
PMC8404221
DOI:
10.1016/j.ejps.2021.105821
PMID:
33781856
Czasopismo naukowe
DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase 1a) is highly expressed in glioma, an aggressive brain tumor, and has been proposed as a therapeutic target for cancer. In the current study, we have used an optimized and validated time-resolved fluorescence energy transfer (TR-FRET)-based DYRK1A assay for high-throughput screening (HTS) in 384-well format. A small-scale screen of the FDA-approved Prestwick drug collection identified the β-carboline, harmine, and four related analogs as DYRK1A inhibitors. Hits were confirmed by dose response and in an orthogonal DYRK1A assay. Harmine's potential therapeutic use has been hampered by its off-target activity for monoamine oxidase A (MAO-A) which impacts multiple nervous system targets. Selectivity profiling of harmine and a broader collection of analogs allowed us to map some divergent SAR (structure-activity relationships) for the DYRK1A and MAO-A activities. The panel of harmine analogs had varying activities in vitro in glioblastoma (GBM) cell lines when tested for anti-proliferative effects using a high content imaging assay. In particular, of the identified analogs, harmol was found to have the best selectivity for DYRK1A over MAO-A and, when tested in a glioma tumor xenograft model, harmol demonstrated a better therapeutic window compared to harmine.
(Copyright © 2021 Elsevier B.V. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies